How big is the Global Pediatric Drugs Market?

The Global Pediatric Drugs Market size is expected to reach USD 130.37 billion in 2024 and grow at a CAGR of 8.36% to reach USD 194.77 billion by 2029. Read More

What is the current Global Pediatric Drugs Market size?

In 2024, the Global Pediatric Drugs Market size is expected to reach USD 130.37 billion. Read More

Who are the key players in Global Pediatric Drugs Market?

BioMarin Pharmaceutical Inc, Horizon Therapeutics plc, Sumitomo Dainippon Pharma Co Ltd, Jazz Pharmaceuticals Inc and Gilead Sciences Inc are the major companies operating in the Global Pediatric Drugs Market. Read More

Which is the fastest growing region in Global Pediatric Drugs Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Global Pediatric Drugs Market?

In 2024, the North America accounts for the largest market share in Global Pediatric Drugs Market. Read More

What years does this Global Pediatric Drugs Market cover, and what was the market size in 2023?

In 2023, the Global Pediatric Drugs Market size was estimated at USD 120.31 billion. The report covers the Global Pediatric Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Pediatric Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Global Pediatric Drugs Market Share

Statistics for the 2023 & 2024 Global Pediatric Drugs market share, created by Mordor Intelligence™ Industry Reports. Global Pediatric Drugs share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Global Pediatric Drugs Industry

The pediatric drugs market is moderately competitive and consists of several major players. A few major players are currently dominating the market in terms of market share. Some prominent players are launching new products to address the unmet challenges in the market, while others are distributing the products. For instance, in April 2019, GSK received approval from the US Food and Drug Administration (FDA) for its intravenous (IV) Benlysta (belimumab), the first medicine approved in the US for children with systemic lupus erythematosus (SLE) from as young as five years of age cranial defects. Some companies currently dominating the market include BioMarin Pharmaceutical Inc., Horizon Therapeutics PLC, Sumitomo Dainippon Pharma Co. Ltd, Gilead Sciences Inc., and Jazz Pharmaceuticals Inc.